GTS Securities’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-209,900
Closed -$14M 3015
2024
Q3
$14M Buy
209,900
+29,700
+16% +$2.73M 0.03% 374
2024
Q2
$21.4M Buy
180,200
+25,700
+17% +$3.25M 0.05% 241
2024
Q1
$16.5M Sell
154,500
-163,400
-51% -$16.5M 0.03% 314
2023
Q4
$31.6M Buy
317,900
+40,300
+15% +$3.39M 0.05% 212
2023
Q3
$28.7M Buy
+277,600
New +$31M 0.05% 220

Other funds holding MRNA

GTS Securities's MRNA Position: Q2 2025 in Review

GTS Securities sold out of Moderna (MRNA) in Q2 2025, closing a stake of 21,737 shares — an estimated $616K sold.

GTS Securities first reported a position in MRNA in Q2 2023 and held it in 7 quarters. The position peaked at $16M in Q3 2023. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • GTS Securities reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • GTS Securities sold 21,737 Moderna shares in Q2 2025, an estimated $616K.
  • GTS Securities first reported a position in Moderna in Q2 2023 and held it in 7 quarters.
  • GTS Securities's Moderna position peaked at $16M in Q3 2023.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.